Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05823545
Other study ID # OMU KAEK 26.12.2019/876
Secondary ID
Status Completed
Phase
First received
Last updated
Start date February 1, 2020
Est. completion date March 3, 2021

Study information

Verified date April 2023
Source Samsun Liv Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study aims to compare the strength of the classical Clavien-Dindo classification system (CDC), which is a Likert scale analysis versus the comprehensive complication index (CCI), a new quantitative evaluation system, in patients undergoing laparoscopic partial nephrectomy (LPN).


Description:

Prospectively collected data of sixty-two patients undergoing LPN with postoperative complications from November 2009 to August 2020 were evaluated retrospectively. Postoperative complications were classified according to the CDCs and calculated using the CCI calculator (https://www.assessurgery.com) quantitatively. Major complications were determined as ≥ grade 3 complications according to the CDC. The complexity of the renal mass was defined according to the RENAL nephrometry score. The cut-off value for CCI was analyzed by the ROC analysis technique. The significance level was taken as p<0.05.


Recruitment information / eligibility

Status Completed
Enrollment 62
Est. completion date March 3, 2021
Est. primary completion date October 7, 2020
Accepts healthy volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - patients with complete data - patients with consent - Patients > 18 year-old - The surgeries performed by the surgeon EO Exclusion Criteria: - Missing data - patients without consent - patients who underwent open or retroperitoneoscopic laparoscopic partial nephrectomy

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Turkey Ondokuz Mayis University, Department of Urology Samsun

Sponsors (1)

Lead Sponsor Collaborator
Samsun Liv Hospital

Country where clinical trial is conducted

Turkey, 

References & Publications (3)

Kim TH, Suh YS, Huh YJ, Son YG, Park JH, Yang JY, Kong SH, Ahn HS, Lee HJ, Slankamenac K, Clavien PA, Yang HK. The comprehensive complication index (CCI) is a more sensitive complication index than the conventional Clavien-Dindo classification in radical — View Citation

Loffel LM, Gross T, Schneider MP, Burkhard FC, Thalmann GN, Bosshard P, Wuethrich PY, Furrer MA. Complication reporting with the Bern Comprehensive Complication Index CCI after open radical prostatectomy: A longitudinal long-term single-center study. Urol Oncol. 2020 Mar;38(3):79.e1-79.e8. doi: 10.1016/j.urolonc.2019.09.021. Epub 2019 Dec 31. — View Citation

Slankamenac K, Nederlof N, Pessaux P, de Jonge J, Wijnhoven BP, Breitenstein S, Oberkofler CE, Graf R, Puhan MA, Clavien PA. The comprehensive complication index: a novel and more sensitive endpoint for assessing outcome and reducing sample size in random — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Postoperative complication Abnormal clinical and laboratory findings that may be seen after surgery and require additional intervention, treatment, or follow-up up to 3 months, postoperatively
Primary Opertaion time From first trocar incision to closure of all incisions during the surgery (minute)
Primary Estimeted blood loss perioperative estimated blood loss during the surgery (mL)
Primary warm ischemia time Its starts when the renal artery and vein are controlled and it ends when reperfusion of the graft kidney starts on the back table during the surgery (minute)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03634540 - A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) Phase 2
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Active, not recruiting NCT00531284 - Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma Phase 1/Phase 2
Recruiting NCT05842044 - NSAID Use After Robotic Partial Nephrectomy Phase 2
Recruiting NCT05387863 - Decision Aid (DA) for Renal Patients N/A
Terminated NCT02669914 - MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors Phase 2
Withdrawn NCT03390413 - Robot-assisted Surgical Resection vs. Cryoablation of Localised Renal Cancer N/A
Completed NCT04933604 - LPN in Patients With High-complex Renal Tumors
Recruiting NCT05119335 - A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma Phase 1/Phase 2
Active, not recruiting NCT03203473 - Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study) Phase 2
Suspended NCT04115254 - Stereotactic Magnetic Resonance Guided Radiation Therapy N/A
Enrolling by invitation NCT02609269 - Decipher Genomics Resource for Intelligent Discovery
Terminated NCT01453595 - BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC) Phase 1/Phase 2
Completed NCT01444456 - Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia N/A
Completed NCT02811250 - Stereotactic Radiotherapy for Renal Cancers N/A
Completed NCT00398814 - Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers Phase 1
Completed NCT00399152 - Perifosine + Sunitinib Malate for Patients With Advanced Cancers Phase 1
Completed NCT00458536 - Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF Phase 1/Phase 2
Recruiting NCT03693014 - A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors Phase 2
Completed NCT00418496 - Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma Phase 1

External Links